BridgeBio’s infigratinib shows improved apnea and ear-infection trends in PROPEL 3
AI Summary- BridgeBio Pharma shared 52-week PROPEL 3 data for oral infigratinib in children with achondroplasia.
- AHI increased 10.4% with infigratinib versus 49.2% with placebo.
- BridgeBio submitted an FDA application and expects a U.S. launch in mid-2027.